Stakeholders, including Uncle Sam, are betting billions on an assumption that’s worked only in some instances and under specific conditions
Hospitals have made astonishingly little progress, but CMS is forcing the issue
Picture a drug that has been compounded for decades and sold at a low price. The FDA approves a new formulation, and the price goes through the roof.
Many problems attributed to outcomes measurement result from poor planning before a program is initiated. A DM expert lays down some ‘must-do’ rules for success in this excerpt from Disease Management and Wellness in the Post-Reform Era, published by Atlantic Information Services Inc.
Health plans have many options to improve how they handle these costly therapies
Richard C. Weiss, BS, MS ; Derek van Amerongen MD, MS ; Gary Bazalo, BS, MS, MBA ; Mark Aagren, MS ; Jonathan R. Bouchard, MS, RPh
By John Marcille
Legislation & Regulation
Complex formula treats urban and rural areas differently
Building provider incentives around drug performance is one way health insurance plans can ensure optimal use
By Thomas Reinke
The Formulary Files
A definitive diagnosis requires a full brain biopsy, but imaging compounds may help identify the deposition of amyloid plaque, which is associated with the disease
Thomas Morrow, MD
Managed Care Outlook